NCT05572983View on ClinicalTrials.gov

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

PHASE2RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2026

Conditions
Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Interventions
DRUG

Chidamide combined with CHOP

A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po

DRUG

Chidamide

Chidamide: 20mg，qw（d1,d4）,po

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER